Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial
#5PRI RANKED
Most Cited Paper
in Mosquito-borne diseases and control
18 Months Post-Publication
Class of 2026
“Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/mosquito-borne-diseases-and-control/2026/
Topics
TAK-003 · tetravalent dengue vaccine · Dengue virus serotypes · Virologically confirmed dengue · Seronegative participants · Seropositive participants · DENV-1 · DENV-2 · DENV-3 · DENV-4 · vaccine efficacy · hospitalised virologically confirmed dengue · active febrile illness surveillance · RT-PCR · subcutaneous vaccination · long-term safety · Dengue-endemic areas · two-dose vaccination schedule · serotype-specific efficacy · dengue-naive individuals
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Mosquito-borne diseases and control Papers, Class of 2026. https://pri.pepkio.com/top-papers/mosquito-borne-diseases-and-control/2026. Accessed 2026-07-17. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459